Flexing against suppression
FLX Bio aims to selectively stop immune suppressors in cancer
FLX Bio Inc. is creating small molecules to dim immunosuppressive actors in the tumor microenvironment without the baggage of the antibodies dominating the immuno-oncology space. Armed with $79 million in series A and B funds, the Flexus Biosciences Inc. spinout has preclinical candidates targeting Tregs and MDSCs, and hopes to enter the clinic this year.
SAB member Philip Greenberg told BioCentury Tregs and myeloid-derived suppressor cells